JB Chemicals & Pharmaceuticals Limited (JBCPL) Records Revenue growth of 16 % to Rs.606 crores for Q1 FY22.

J. B. Chemicals & Pharmaceuticals Limited (JBCPL), one of the fastest growing pharmaceutical companies in India, announced its financial results for the first quarter ended 30^th June, 2021.

Quarterly Financial Performance – Q1 FY22 vs Q1 FY21

For the first quarter ended 30^th June 2021, the Company recorded revenue of Rs. 606 crores as compared to Rs. 522.3 crores, registering growth of 16 % over the corresponding quarter ended 30^th June, 2020. EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 5 % to Rs. 163.7 crores as compared to Rs. 155.4 crores. EBITDA margin for the quarter was at 27 % as compared to 29.8 %. Profit after Tax was flat at Rs. 118.9 crores as compared to Rs. 119.4 crores

Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JBCPL said, “The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry. Our new Go- To-Market(GTM) model has been implemented and early signs are encouraging, which is reflected in the strong performance of flagship brands and new launches. While demand trends in international business continue to be volatile (given the COVID situation); our key markets like US, S Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival. We expect the performance to improve in select pockets of our international business. Going forward, our priority continues to build on cost efficiency measures while maintaining the same growth momentum”